Logo

Genedata Licenses PathoLead to Novartis Institute for Tropical Diseases

Jun 30, 2005

NEW YORK, June 30 (GenomeWeb News) - Genedata today said that the Novartis Institute for Tropical Diseases in  Singapore will use its Phylosopher PathoLead software to study progressive infectious and parasitic disease.

 

Specifically, the Phylosopher software will serve as an organization-wide scientific management system for proprietary data integration.

 

Scientists at NITD will use the software to identify and validate target candidates and prioritize the development of drug classes. Research at NITD focuses on Dengue fever and tuberculosis. The ultimate goal would be to develop an anti-viral treatment, the group said.

 

Almost exactly two years ago, Basel, Switzerland-based Genedata licensed the PathoLead suite of tools to Novartis' Institutes for BioMedical Research.

Breaking News
The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.